

# Cumulative Index 1990

## Volume 16

---

<i>February</i>	<b>SCLERODERMA</b> , pages 1-249
<i>May</i>	<b>VASCULITIC SYNDROME</b> , pages 251-497
<i>August</i>	<b>EPIDEMIOLOGY OF RHEUMATIC DISEASE</b> , pages 499-789
<i>November</i>	<b>EXERCISE AND ARTHRITIS</b> , pages 791-1023

---

*Note:* Page numbers of issues and articles are in **boldface** type.

- Abdominal muscles, back exercise and, 948-950
- Acetylation status, in scleroderma, 43
- Acetylcholine, in vascular muscle regulation, 255
- N-Acetylcysteine, in scleroderma, 220
- Acquired immunodeficiency syndrome. See also *Human immunodeficiency virus infection*.
  - antiphospholipid antibody syndrome and, 481-482
- Acrodermatitis chronica atrophicans, in Lyme disease, 601-602, 610
- Active exercise, in inflammatory arthritis, 849
  - in shoulder impingement syndrome, 983-984
- Activities of daily living, disability in, 748-750
- Aerobic capacity, 799-800
  - in inflammatory arthritis, 847-848
  - in resistance training, 937
  - measurement of, 994-995
- Aerobic exercise, 832, 1000
  - bicycling as, 872-873
  - in back pain, 946
  - in inflammatory arthritis, 852-853
- AIDS (acquired immunodeficiency syndrome). See also *Human immunodeficiency virus infection*.
  - antiphospholipid antibody syndrome and, 481-482
- Alcohol consumption, osteoporosis and, 725
- Alfalfa sprouts, in systemic lupus erythematosus, 629-630
- Allergic angiitis, 277-280, 309-312
  - epidemiology of, 674
- Allopurinol, in gout, 547-548
- Alpha-adrenergic receptors, in vascular smooth muscle function, 253-254
- Alpha-granules, in scleroderma, 64
- Alzheimer's disease, rheumatoid arthritis and, 528
- Amenorrhea, osteoporosis and, 723
- American College of Rheumatology, fibromyalgia classification of, 682-686, 690
- American Rheumatism Association, disease classification/criteria of, juvenile rheumatoid arthritis, 582
  - rheumatoid arthritis, 513-514
  - scleroderma, 2
  - systemic lupus erythematosus, 617
- Aminoacetoneitrile, in scleroderma, 218
- Aminocaproic acid, in scleroderma, 218
- Anaphylactoid purpura. See *Henoch-Schönlein vasculitis*.
- Anchorin CII, in fibroblast attachment to matrix, 96
- Androgens, rheumatoid arthritis and, 526-527
- Anemia, in trained athletes, 818-820
- Angiography, in vasculitic syndromes. See under *Roentgenographic findings*.
- Angiotensin, in vascular muscle regulation, 255-256, 258
- Angiotensin converting enzyme inhibitors, in scleroderma, 8, 220-222, 650

- Animal models, for fibrosis/scleroderma. See *Scleroderma, animal models for*.
- Ankle, exercise for, 960
- Ankylosing spondylitis, aquatic therapy in, 918
- course of, 570-571
- diagnostic criteria for, 556-558
- epidemiology of, 551-579
- in U.S.S.R., 776
- etiology of, 564-569
- exercise for, 865-866, 918
- HLA antigens in, 559-561, 564-569
- inflammatory bowel disease and, 555
- juvenile, 553, 590-591
- late-onset, 553-554
- prevalence of, 556-561
- prognosis for, 570-571
- racial factors in, 558-559
- sex distribution of, 561
- spectrum of, 551-552
- Antacids, osteoporosis and, 729
- Anti-68K antibodies, in mixed connective tissue disease, 189
- Anti-Ku antibodies, in scleroderma/polymyositis overlap, 187-188
- Anti-RNA polymerase I antibodies, in scleroderma, 173-174
- Anti-Scl-70 antibodies, in scleroderma, 170-171
- Anti-Th antibodies, in scleroderma, 177-178
- Anti-To antibodies, in scleroderma, 177-178
- Anti-U1 RNP antibodies, in mixed connective tissue disease, 189
- Anti-U3-RNP-associated fibrillarin antibodies, in scleroderma, 176-177
- Antibiotics, in Lyme disease, 611
- Antibodies, in idiopathic inflammatory myopathies, 660-661
- Anticardiolipin antibodies, in antiphospholipid antibody syndrome, 474-475
- in Behçet's disease, 428
- Anticentromere antibodies, in scleroderma, 18-20, 172-173
- Anticoagulants, in antiphospholipid antibody syndrome, 472-474, 484-485
- Anticytoplasmic autoantibodies, in Wegener's granulomatosis, 386-389
- Antifibrillar antibodies, in scleroderma, 176-177
- Antimitochondrial antibodies, in scleroderma, 178
- Antinuclear antibodies, in Raynaud's phenomenon, 18, 20, 26
- in rheumatoid vasculitis, 453
- in scleroderma, 18-20, 45-46, 125-126, 169-183
- Antiphospholipid antibody syndrome, 471-490
- antibody detection tests in, 471-475
- anticardiolipin antibodies in, 474-475
- cardiac manifestations of, 480-481
- clinical features of, 475-482
- cutaneous lesions in, 479-480
- drug-induced, 481
- familial factors in, 481
- in human immunodeficiency virus infection, 481-482
- lupus-like anticoagulants in, 472-474
- neurologic events in, 478-479
- obstetric complications in, 477-478, 483, 485
- pathology of, 482-483
- pathophysiology of, 483-484
- reagents in, 472
- thrombocytopenia in, 476-477
- thrombosis in, 475-476, 482-484
- treatment of, 484-485
- Antiplatelet agents, in polyarteritis nodosa, 357
- in scleroderma, 21, 230-231
- Antithymocyte globulin, in scleroderma, 218
- Aortic arch syndrome. See also *Takayasu's arteritis*.
- in relapsing polychondritis, 443
- Aortic insufficiency, in Cogan's syndrome, 435, 437
- Aortitis, idiopathic. See *Takayasu's arteritis*.
- in Cogan's syndrome, 434-435, 437
- in relapsing polychondritis, 443
- Aortoarteritis, epidemiology of, 671-672
- Apheresis, in scleroderma, 233-235
- Aquatic therapy, 841, 915-929
- benefits of, 916-920
- buoyancy and, 922
- contraindications for, 925-926
- guidelines for, 927-928
- in inflammatory arthritis, 854, 867
- in resistance training, 939-940
- indications for, 924-925
- movement in, Newton's laws and, 922-923
- patient evaluation for, 924-927
- pool requirements for, 924
- precautions in, 925-926
- resistance in, 923
- water physical properties and, 921-923
- Arteriography, in vasculitic syndromes. See under *Roentgenographic findings*.
- Arteriosclerosis. See *Atherosclerosis*.
- Arteritis. See also *Vasculitic syndromes*.
- epidemiology of, giant cell, 668-671
- polyarteritis nodosa, 672-673
- Takayasu's, 671-672
- Arthritis, enteric, exercise in, 865-866
- exercise in. See *Exercise; Inactivity*.
- in polyarteritis, 349
- in Takayasu's arteritis, 414
- in urticarial vasculitis, 315
- in Wegener's granulomatosis, 381
- inactivity in. See *Exercise; Inactivity*.

- inflammatory. See *Inflammatory arthritis*;  
specific type.  
mortality in, 816-817  
psoriatic. See *Psoriatic arthritis*.  
rheumatoid. See *Rheumatoid arthritis*.  
Arthritis Impact Measurement Scales, 750  
Aspiration pneumonia, in scleroderma, 212  
Aspirin, in antiphospholipid antibody syn-  
drome, 485  
in Kawasaki syndrome, 370-372  
in scleroderma, 230-231  
Asthma, in Churg-Strauss syndrome, 262-  
263, 393  
Atherosclerosis, pathogenesis of, arteritis  
and, 344-345  
with giant cell arteritis, 297-298  
Athletics. See *Exercise*; *Sports*.  
Audiovestibular symptoms, in Cogan's syn-  
drome, 433, 435  
Autoantibodies, in scleroderma, 45-46, 169-  
183  
anti-nuclear particle PM-Scl, 174-176  
anti nucleolar 7-2 ribonucleoprotein,  
177-178  
anti-RNA polymerase I, 173-174  
anti-Scl-70, 170-171  
anti U3-RNP-associated fibrillarin, 176-  
177  
antacentromere, 18-20, 172-173  
antimitochondrial, 178  
Autoimmunity, in scleroderma, 129-131,  
148  
in Wegener's granulomatosis, 386-389  
Axillary artery, giant cell arteritis of, 294  
Azathioprine, in polyarteritis nodosa, 356  
in rheumatoid vasculitis, 456  
in scleroderma, 224-225  
Azulfidine, in scleroderma, 218  
Azuridine, in scleroderma, 218  
incidence of, 699  
leisure time activity and, 709  
motor vehicle driving and, 707  
occupational risk factors in, 702-706  
postural disorders and, 708-709  
pregnancy and, 708  
prevention of, 709-710  
psychosocial factors in, 708  
smoking and, 707  
Basic calcium phosphate crystals, in osteoar-  
thritis, 506  
Bed rest, controversy on, 893  
effects of, 791-798, 846  
joint positioning in, 866-867  
retraining after, 799-800  
Behçet's disease, 423-431  
arterial lesions in, 427-428  
histopathology of, 424  
mucocutaneous lesions in, 423-425  
neurologic involvement in, 425-426  
ocular involvement in, 425  
pathogenesis of, 428  
roentgenographic findings in, 304  
treatment of, 428-430  
venous disease in, 426-427  
Benoxaprofen, in scleroderma, 218  
Beta-adrenergic receptors, in vascular  
smooth muscle function, 254  
Beta-thromboglobulin, in scleroderma, 21  
Bicycling, 871-886  
accessories for, 880-882  
arthritis patients and, 876-877  
benefits of, 871-877  
biomechanics of, 874-875  
choosing bicycle for, 877-883  
in conditioning programs, 883-885  
outdoor, 883-885  
physics of, 873-874  
physiologic response to, 875-876  
stationary, 883  
Biliary cirrhosis, primary, antimitochondrial  
autoantibodies in, 178  
with scleroderma, 191-192  
Biodex exercise machine, 852  
Biopsy, in giant cell arteritis, 404-405  
in polyarteritis nodosa, 272, 353  
in rheumatoid vasculitis, 451-452  
in Wegener's granulomatosis, 277, 385  
Bleomycin, scleroderma induced by, 45, 67,  
154, 646  
Blood pressure, high. See *Hypertension*.  
Blood vessels, pathophysiology of, 259  
physiology of, 251-260  
smooth muscle function in, 251-254  
smooth muscle regulation in, 254-258  
structure of, 251  
Bone density, exercise effects on, 946-947  
inactivity effects on, 793  
measurement of, 720-721  
Back pain, body build and, 706-707  
demographic characteristics of, 701-702  
epidemiology of, 699-716  
exercise for, 945-970  
abdominal musculature synergies in,  
948-950  
anatomic movement constraints and,  
947  
benefits of, 945-947  
erector spinae and, 953-954  
flexibility, 957-960  
lifting and, 951-952, 954-957  
lumbodorsal fascia and, 953-954  
neutral spine concept in, 963-965  
range of motion, 957-960  
strengthening, 960-963  
forward flexibility and, 709  
hereditary predisposition to, 709

- Borrelia burgdorferi*, as Lyme disease causative agent, 602-603. See also *Lyme disease*.
- Brachiocephalic arteries, giant cell arteritis of, 294-296
- Takayasu's arteritis of, 298-299
- BRIME exercise program, 850
- Bronchiolitis obliterans, in D-penicillamine therapy, 212
- Bronchoalveolar lavage, in scleroderma, 16, 204-206
- Buerger's disease, 463-470
- arteriography in, 466-467
- clinical features of, 464-466
- epidemiology of, 464
- etiology of, 467-468
- histopathology of, 287-290
- pathology of, 468
- roentgenographic findings in, 300-302
- treatment of, 468-469
- Bury type of erythema elevatum diutinum, 316
- Caffeine consumption, osteoporosis and, 726
- Calcium, dietary, osteoporosis and, 726
- in vascular smooth muscle function, 252-254
- loss of, in inactivity, 793
- Calcium pyrophosphate dihydrate crystals, in osteoarthritis, 505-506
- L-Canavanine, in systemic lupus erythematosus, 629-630
- Cancer, lung, in scleroderma, 212
- Captopril, in scleroderma, 221-222
- Carbohydrate metabolism, inactivity effects on, 795
- Carboprostacyclin, in scleroderma, 236
- Carcinoma, lung, in scleroderma, 212
- Cardiolipin, antibodies to, in antiphospholipid antibody syndrome, 474-475
- Cardiovascular disease. See also *Coronary heart disease*; *Myocardial infarction*.
- in antiphospholipid antibody syndrome, 480-481
- in Cogan's syndrome, 435, 437
- in Kawasaki syndrome, 366
- in polyarteritis, 350-351
- in relapsing polychondritis, 443
- in rheumatoid vasculitis, 450
- in Takayasu's arteritis, 415
- in Wegener's granulomatosis, 380
- Cardiovascular effects, of bicycling, 875-876
- of exercise, in aquatic therapy, 917-918
- of inactivity, 795-798, 803-813
- coronary heart disease, 807-810
- hypertension and, 803-805
- mortality, 807-810
- serum lipids and, 805-806
- Carotid artery, Takayasu's arteritis of, 298-299, 413
- Cassidy classification, of juvenile rheumatoid arthritis, 582-583
- Cauda equina syndrome, in ankylosing spondylitis, 571
- Central nervous system, Behçet's disease effects on, 425-426
- polyarteritis of, 349-350
- primary angiitis of, 287
- rheumatoid vasculitis of, 450
- Centromere, autoantibodies against, in scleroderma, 18-20, 172-173
- Centromere autoantigens, molecular structure of, 173
- Cervical spine, exercise and, 861, 868
- Chemicals, in scleroderma etiology, 5, 43-45, 146, 155, 645-646
- Chemotactic activity, of fibroblasts, 97-98
- Childhood rheumatic disease. See also *Juvenile rheumatoid arthritis*.
- age at onset of, 581-582
- ankylosing spondylitis, 553, 590-591
- CREST syndrome, 595
- dermatomyositis, 593-594
- eosinophilic fasciitis, 595
- epidemiology of, 581-599
- fibromyalgia, 692
- Henoch-Schönlein vasculitis, 675-676
- in ulcerative colitis, 592
- Kawasaki syndrome, 676-677
- mixed connective tissue disease, 595
- myositis, 655-663
- psoriatic arthritis, 591-592
- Reiter's syndrome, 591
- scleroderma, 594-595
- spondyloarthropathies, 590-592
- systemic lupus erythematosus, 592-593
- Chlamydia* infection, in spondyloarthropathies, 568
- Chlorambucil, in Behçet's disease, 430
- in scleroderma, 209, 224-225
- Chlorinated solvents, scleroderma induced by, 43-44
- Chlorpromazine, antiphospholipid antibodies induced by, 481
- Cholesterol, exercise effects on, 805-806
- Chondrocalcinosis, osteoarthritis and, 506
- Chorea, in antiphospholipid antibody syndrome, 479
- Chromosomal instability, in scleroderma, 46-47
- Churg-Strauss syndrome, clinical features of, 393-394
- epidemiology of, 262-263, 674
- giant cell arteritis with, 404
- histopathology of, 272, 275-277
- phases of, 393
- prognosis of, 263
- treatment of, 394

- vs. Wegener's granulomatosis, 377, 392-394
- Claudication, in Buerger's disease, 464-465  
in Takayasu's arteritis, 413  
jaw, in giant cell arteritis, 402
- Coagulation disorders, in antiphospholipid antibody syndrome, 472-477  
in Behçet's disease, 428  
in rheumatoid vasculitis, 452  
in scleroderma, 21
- Cogan's syndrome, 433-439  
aortic insufficiency in, 435, 437  
clinical findings in, 435  
etiology of, 433-434  
pathogenesis of, 433-434  
pathology of, 434  
roentgenographic findings in, 304  
treatment of, 437-438  
vasculitis in, 435
- Colchicine, in Behçet's disease, 428-429  
in gout, 548  
in scleroderma, 209, 222-223
- Collaborative international epidemiologic studies, 763-772  
barriers to, 769-770  
countries involved in, 767-768  
definition of, 763-764  
facilitation of, 768-769  
reasons for, 764-767  
recommendations for, 770-771
- Collagen, antibodies to, in scleroderma, 126  
chemotactic activity of, 97-98  
contracted gels of, fibroblast metabolism and, 100-102  
fibroblast attachment to, 94-95  
genes of, control of, 109-123  
in scleroderma, 111-113  
normal, 114-122  
regulatory elements of, 117-120  
RNA of, in scleroderma, 111-113  
synthesis/degradation of, chemical mediator effects on, 132-133  
in scleroderma, in animal models, 162-163  
three-dimensional gels of, fibroblast morphology and, 99-100  
type of, in scleroderma, in animal models, 161
- Collagen diseases. See also specific disease, e.g., *Scleroderma*.  
types of, 185
- Collagenase, fragments of, chemotactic activity of, 97-98  
synthesis of, chemical mediator effects on, 132-133
- Complement system, in rheumatoid vasculitis, 452-453  
major histocompatibility complex genes and, 36-38  
scleroderma and, 41-42, 132
- Computed tomography, in scleroderma with pulmonary involvement, 204
- Conditioning, physical. See *Exercise*.
- Connective tissue disease. See also specific disease, e.g., *Scleroderma*.  
in children, 595  
myositis with, 655-663  
Raynaud's phenomenon and. See *Raynaud's phenomenon*.
- Contractures, in inflammatory arthritis, 847
- Coronary heart disease, asymptomatic hyperuricemia and, 547  
exercise and, 807-810  
gout and, 546-547  
in Kawasaki syndrome, 266, 286, 304, 366  
in rheumatoid arthritis, 817
- Corticosteroids, in antiphospholipid antibody syndrome, 484-485  
in Behçet's disease, 428  
in Cogan's syndrome, 437  
in eosinophilic fasciitis, 194  
in giant cell arteritis, 406-407  
in polyarteritis nodosa, 262, 355-357  
in polymyalgia rheumatica, 334-336  
in rheumatoid vasculitis, 454-455  
in scleroderma, 218, 234  
in Takayasu's arteritis, 417-418  
osteoporosis and, 728
- Cough, in scleroderma, 200
- Coxsackievirus, in inflammatory myopathies, 660
- Cranial arteritis. See *Giant cell arteritis*.
- Cranial neuropathy, in relapsing polychondritis, 442
- CREST syndrome, antibodies in, 18-20, 126, 173  
epidemiology of, 595  
primary biliary cirrhosis with, 191-192  
pulmonary hypertension in, 210-211  
Raynaud's phenomenon and, 17-18  
Sjögren's syndrome with, 193
- Crohn's disease, ankylosing spondylitis with, 569
- Cross-training, in muscle function maintenance, 841-842
- Cryoglobulins, in rheumatoid vasculitis, 453
- Crystal deposition disorders. See also *Gout*.  
in osteoarthritis, 505-506
- Cutaneous vasculitis, 309-324  
Behçet's disease, 423-425  
erythema elevatum diutinum, 316-318  
granulomatous, 322-323  
Henoch-Schönlein, 313-315  
in antiphospholipid antibody syndrome, 479-480  
in rheumatoid arthritis, 447-449, 451, 454  
livedoid, 320-322  
necrotizing, 309-312  
nodular, 322

Cutaneous vasculitis (*Continued*)

- polyarteritis nodosa, 318-319, 347, 349, 352
  - relapsing polychondritis, 441-442
- Takayasu's arteritis, 414-415
- urticarial, 315-316
- Wegener's granulomatosis, 380-381
- Cybox II exercise machine, 852
- Cyclic guanosine monophosphate, in vascular muscle regulation, 256
- Cyclofenil, in scleroderma, 223-224
- Cyclophosphamide, in polyarteritis nodosa, 356
  - in rheumatoid vasculitis, 455
  - in scleroderma with pulmonary involvement, 210
  - in Takayasu's arteritis, 418
  - in Wegener's granulomatosis, 389-390
- Cyclosporine, in Behçet's disease, 430
  - in scleroderma, 218
- Cytokines, in collagen gene control, 110, 121-122
  - in scleroderma, 60-63, 128-129, 132-133, 147-148, 208-209
- Cytomegalovirus infection, polyarteritis nodosa and, 262
- Dapsone, in giant cell arteritis, 406-407
- Dazoxiben, in Raynaud's phenomenon, 65
- Deafness, in Cogan's syndrome, 433
- Degos' disease, antiphospholipid antibodies and, 479-480
- DeLateur exercise program, 850-851
- DeLorme exercise program, 850-851
- Dementia, senile, rheumatoid arthritis and, 528
- Dermatomyositis, epidemiology of, 655-663
  - exercise for, 864-865
  - juvenile, 593-594
  - with scleroderma, 187-189
- Dextran therapy, in scleroderma, 225-226
- Diabetes mellitus, exercise and, 807
  - osteoarthritis and, 506
  - osteoporosis and, 728
- Diet, osteoporosis and, 726-727
- Digits, rheumatoid vasculitis of, 447
- Dimethyl sulfoxide, in scleroderma, 226-228
- Dipyridamole, in scleroderma, 230-231
- Disability, 741-761
  - arthritis measuring instruments in, 750-751
    - definition of, 743-747
    - impacts of, 751-755
    - in fibromyalgia, 694
    - in gout, 542-543
    - in osteoarthritis, 507-508
    - individual impacts of, 753-755
    - measurement of, 747-751

- mental, definition of, 745
  - physical, definition of, 745
  - measurement of, 747-748
  - prevalence rates for, 741-742
  - probability curves for, 741-742
  - social, 753-754
    - definition of, 745
    - measurement of, 748-750
    - societal impacts of, 751-753
    - sociomedical model of, 746-747
    - types of, 745-746
    - work, 748-750
  - DNA topoisomerase I, autoantibodies against, 170-171
  - Down's syndrome, rheumatoid arthritis and, 528
  - Drugs, antiphospholipid antibodies induced by, 481
    - osteoporosis and, 728-729
  - Dyspnea, in scleroderma, 199-200
  - Ear, Wegener's granulomatosis effects on, 379, 381-382, 392
  - Edworthy criteria, for systemic lupus erythematosus classification, 617-618
  - Elbow, exercise for, 861
  - Elderly persons, exercise for, 855
    - polymyalgia rheumatica in, 325-327
    - rheumatoid arthritis in, 331-332
  - Enalapril, in scleroderma, 221-222
  - Endometriosis, osteoporosis and, 724
  - Endothelial cells, chemical mediator effects on, 133
    - lymphocytes of, fibroblast interactions with, 53-73
    - cell injury hypothesis and, 56-63
    - fibrosis and, 67-68
    - functional observations in, 55-56
    - histology of, 54-55
    - in intravascular environment, 63-67
  - vascular, injury of, arteritis and, 343-344
  - atherosclerosis and, 344-345
  - in Kawasaki syndrome, 369-370
  - physiology of, 255-258
  - viral effects on, 342
- Endothelin, in vascular smooth muscle regulation, 258, 343-344
- Endothelium-derived hyperpolarizing factor, in vascular muscle regulation, 256-257
- Endothelium-derived relaxing factors, in vascular muscle regulation, 256-257, 259, 343-344
- Endurance training, in inflammatory arthritis, 852-853
  - in muscle function maintenance, 840-842
- Enteric arthritis, exercise for, 865-866
- Environmental factors, in scleroderma, 5, 39, 43-45, 146

- Eosinophilia, in Churg-Strauss syndrome, 272, 275-276, 393
- Eosinophilia myalgia syndrome, L-tryptophan-induced, 646
- Eosinophilic fasciitis, in children, 595
- mast cell activity in, 146
- vs. scleroderma, 194
- with scleroderma, 193-194
- Epidemiology, of rheumatic disease, ankylosing spondylitis, 551-579
- childhood, 581-599
- collaborative international studies on, 763-772
- fibromyalgia, 681-698
- gout, 539-550
- hip fractures from osteoporosis, 717-740
- hyperuricemia, 539-550
- idiopathic inflammatory myopathy, 655-665
- in U.S.S.R., 773-781
- low back pain, 681-698
- Lyme disease, 601-615
- osteoarthritis, 499-512
- osteoporosis, 717-740
- prolapsed lumbar intervertebral disc, 681-698
- rheumatoid arthritis, 513-537
- risk factors in, 777-780. See also specific disease.
- spondyloarthropathy, 551-579
- systemic lupus erythematosus, 617-639
- systemic sclerosis, 641-654
- vasculitic syndromes, 667-680
- Epinephrine, in vascular smooth muscle regulation, 258
- Erythema elevatum diutinum, 316-318
- Erythema migrans, in Lyme disease, 601, 606, 609-610
- Esophageal motility, in scleroderma, Raynaud's phenomenon and, 17
- Estrogens, osteoporosis and, 722-724, 728
- rheumatoid arthritis and, 526-527
- smoking and, 724-725
- Ethylene diamine tetraacetic acid, in scleroderma, 218
- Exercise, active, in inflammatory arthritis, 849
- in shoulder impingement syndrome, 983-984
- aerobic capacity in. See *Aerobic capacity*.
- anemia in, 818-820
- aquatic therapy in, 841, 854, 867, 915-929
- back and, 945-970
- benefits of, in back pain, 945-947
- in resistance training, 931-934, 937-938
- bicycling in, 871-886
- blood characteristics in, 818
- cardiovascular effects of. See *Cardiovascular effects*.
- compliance with programs, 856
- concentric contraction in, 936
- coronary heart disease and, 807-810, 821-822
- cross-training, 841-842
- diabetes and, 807
- eccentric contraction in, 936-937
- effects of, 895-897
- endurance training, 840-842, 852-853
- fibrinogen and, 821-822
- fibrinolysis in, 822-823
- for ankle, 860
- for cervical spine, 861, 868
- for elbow, 861
- for foot, 860
- for hand, 861
- for hip, 859, 868
- for interphalangeal joints, 868
- for knee, 859-860, 868
- for shoulder, 860-861
- for wrist, 861
- frequency of, 936
- hematocrit in, 818-820
- hypertension and, 803-805
- importance of, 791-801
- in connective tissue disease, 845-870
- in disuse muscle atrophy, 837-844
- in elderly patients, 855
- in inflammatory arthritis, 845-870
- in inflammatory myopathy, 864-865
- in juvenile rheumatoid arthritis, 866-868
- in muscle function maintenance, 840-844
- in progressive systemic sclerosis, 863-864
- in rheumatoid arthritis, 859-862
- in shoulder impingement syndrome, 971-988
- in spondyloarthropathy, 865-866
- in systemic lupus erythematosus, 862-863
- intensity of, 936
- isokinetic, 843-844, 985-986
- isometric, 842, 849-850, 937, 984
- isotonic, 842-843, 850-852
- joint assessment before, 854-855
- kinesiology and, 989-1002
- lack of. See *Inactivity*.
- longevity/mortality and, 807-810, 815-816
- musculoskeletal effects of, 827-836
- obesity and, 806-807
- osteoporosis and, 723-726, 730
- pain considerations in, 855
- passive, 849, 982-983
- plasma volume in, 818-819
- platelet function in, 820-821
- power training, 842
- preparation for, 855
- progressive resistance in, 936
- range-of-motion. See *Range-of-motion exercise*.



Exercise (*Continued*)

- recreational, 854, 867. See also *Aquatic therapy; Bicycling*.
- repetition in, 936
- resistance training as, 931-943
- rest periods in, 936
- running as, 887-914
- sequencing of, in inflammatory arthritis, 856
- serum lipids and, 805-806
- sets in, 936
- speed training, 842
- strengthening, 867, 984-985, 999-1000
- stretching, 853-854, 1000
- volume of, 936
- walking as, 887-914
- warm-ups in, 998-999
- Extracellular matrix-fibroblasts interactions. See under *Fibroblasts*.
- Extractable nuclear antigen, RNase sensitive, antibodies to, in mixed connective tissue disease, 189
- Eye, vasculitic syndrome effects on, antiphospholipid antibody syndrome, 478-479
  - Behçet's disease, 425
  - giant cell arteritis, 405-406
  - polyarteritis, 351
  - rheumatoid, 450
  - Takayasu's arteritis, 413-414
  - Wegener's granulomatosis, 378-379, 381-382, 385
- Factor VIII, in polymyalgia rheumatica, 329-330
  - in scleroderma, 66
- Factor XIII, in scleroderma, 231
- Fasciitis, eosinophilic, in children, 595
  - mast cell activity in, 146
  - with scleroderma, 193-194
- Felty's syndrome, genetic factors in, 521
- Femoral artery, giant cell arteritis of, 296-297
- Fertility, rheumatoid arthritis and, 523-524
- Fetal loss, antiphospholipid antibody syndrome and, 477-478, 483, 485
  - rheumatoid arthritis and, 523-524
- Fibrillar, U3-RNP-associated, autoantibodies to, 176-177
- Fibrin stabilizing factor, in scleroderma, 231
- Fibrinogen levels, exercise and, 821-822
- Fibrinolysis, disorders of, in scleroderma, 66-67
  - exercise and, 822-823
- Fibroblasts, chemical mediator effects on, 132-133
  - collagen gene control in, 109-123
    - in scleroderma, 111-113
    - normal, 114-122
  - regulatory elements of, 117-120
  - transforming growth factor in, 120-122
- endothelial cell lymphocytes interactions with, 53-73
- extracellular matrix interactions of, 93-107
  - attachment, 94-95
  - chemotactic activity in, 97-98
  - contracted collagen gels in, 100-102
  - control of, 96-97
  - integrins in, 95-96
  - procollagen peptides in, 98-99
  - receptor protein mediation in, 95-96
  - three-dimensional collagen gels in, 99-100
- in scleroderma, pulmonary involvement and, 206, 208-209
- metabolism of, collagen gels and, 100-102
- morphology of, collagen gels and, 99-100

- Fibromyalgia, age at onset of, 691
  - age distribution of, 690
  - classification of, 682-686, 690
  - clinical course of, 693-694
  - concomitant, 689-690
  - definition of, 681-686
  - diagnosis of, 682-683
  - disability in, 694
  - economic status and, 691
  - education status and, 691
  - epidemiology of, 681-698
  - identification of, 686-688
  - in childhood, 692
  - marital status and, 692
  - natural history of, 693-694
  - onset of, 692
  - prevalence of, 688-690
  - primary, 689-690
  - psychological status in, 693
  - racial distribution of, 691
  - rheumatoid arthritis with, 694-695
  - secondary, 689-690
  - sex distribution of, 691
  - tender points in, 681-683
  - trigger points in, 681
  - vs. fibrositis, 682
  - vs. polymyalgia rheumatica, 330
- Fibronectin, chemotactic activity of, 97
  - in fibroblast attachment to matrix, 95-96
  - in scleroderma, gene modification in, 59
  - pulmonary involvement and, 206, 208
  - synthesis of, chemical mediator effects on, 132
- Fibrosis. See also *Fibroblasts*.
  - animal models for. See *Scleroderma, animal models for*.
  - interstitial pulmonary, in scleroderma, 199-210
  - mast cell activity in, 141-151
  - pathogenesis of, fibroblast-matrix interactions in, 93-107



- vascular disease and, 67-68
- Fitness, fibrinogen levels in, 821-822
- inactivity effects on, 792-793
- testing for, 991-998
  - aerobic function measurement, 994-995
  - kinanthropometry, 995-998
  - pain evaluation, 998
  - physical examination in, 991-992
  - range of motion measurement, 992
  - strength assessment, 992-994
- Flexibility, in running, 891-892
- Fluoride, osteoporosis and, 726
- 5-Fluorouracil, in scleroderma, 224-225
- Foot, exercise for, 860
- Football, osteoarthritis and, 504
- Fractures, of hip. *See Osteoporosis.*
  
- Gallium-67 scan, in scleroderma with pulmonary involvement, 203-204
- Gamma globulin, in Kawasaki syndrome, 371
- Gangrene, in antiphospholipid antibody syndrome, 479
  - in Buerger's disease, 465-466
- Gastrectomy, osteoporosis and, 728
- Gastrointestinal system, rheumatoid vasculitis effects on, 450
- Genetic factors, in scleroderma, 3-5, 31-51, 643-645
  - C4 null alleles and, 41-42
  - case reports in, 31-32
  - chromosomal instability in, 46-47
  - collagen gene control and, 109-123
  - environmental factors and, 43-45
  - immunologic abnormalities in, 45-46
  - major histocompatibility complex 1 and, 32-36
    - class II, 38-41
  - major histocompatibility complex 2 and, 36-38
  - sex predisposition in, 31-32
- Giant cell arteritis, 399-409
  - biopsy in, 404-405
  - clinical findings in, 401-404
  - course of, 407
  - diagnosis of, 404-406
  - epidemiology of, 265-266, 399-400, 668-671
  - genetic factors in, 400-401
  - histopathology of, 281-282
  - polymyalgia rheumatica and, 327, 332-333, 336
  - prognosis of, 265-266
  - roentgenographic findings in, 293-298
  - treatment of, 406-407
  - vs. Takayasu's arteritis, 298
- Glucocorticoids. *See Corticosteroids.*
- Glycosaminoglycans, in scleroderma, in animal models, 161-162
  - synthesis of, chemical mediator effects on, 132
- Glycosaminoglycans fraction, in urine of scleroderma patients, 154-155
- Goodpasture's syndrome, in D-penicillamine therapy, 212
- Gout, coronary heart disease and, 546-547
  - definition of, 540
  - epidemiology of, 539-550
    - in U.S.S.R., 776
  - hyperuricemia and, 544-547
  - impact of, 542-543
  - incidence of, 540-541
  - prevalence of, 541-542
  - prevention of, 547-548
  - racial factors in, 543-544
  - risk factors for, 543-544
- Gracovetsky model of lifting, 955-957
- Graft-versus-host disease, mast cells and, 143-144
  - scleroderma and, 131, 153-154
- Granulomatosis, Wegener's. *See Wegener's granulomatosis.*
- Granulomatous angiitis/vasculitis. *See also Churg-Strauss syndrome; Wegener's granulomatosis.*
  - cutaneous, 322-323
  - of central nervous system, 287
- Griseofulvin, in scleroderma, 219
- Growth factors, in collagen gene control, 120-122
  - scleroderma and, 62, 132-133
- Guanine nucleotide regulator protein, in vascular smooth muscle function, 254
  
- Hairy cell leukemia, polyarteritis nodosa in, 342
- Hand, exercise for, 861
  - osteoarthritis of, disability in, 507
  - natural history of, 508
  - prevalence of, 501
- Headache, in antiphospholipid antibody syndrome, 479
  - in giant cell arteritis, 401
- Heart. *See also Cardiovascular disease; Cardiovascular effects.*
  - enlargement of, in scleroderma, 158
  - Raynaud's phenomenon manifestations in, 55-56
- Heberden's nodes, 505
- Hemangioma, mast cells in, 142
- Hematocrit, exercise and, 818-820
- Hematology, of inactivity, 815-824
  - arthritis and, 816-817
  - blood characteristics in, 818
  - cardiovascular risk and, 821-822

**Hematology** (*Continued*)

- fibrinogen levels, 821-822
- fibrinolysis, 822-823
- hematocrit, 818-820
- longevity and, 815-816
- platelet function, 820-821
- Henoch-Schönlein vasculitis, 313-315
  - epidemiology of, 263-264, 675-676
  - etiology of, 263-264
  - histopathology of, 281
  - prognosis of, 264
- Heparin, in antiphospholipid antibody syndrome, 484-485
- Hepatitis B, polyarteritis nodosa and, 261-262, 342, 351, 673
- Hip, exercise for, 859, 868
  - fractures of, in osteoporosis. *See Osteoporosis.*
  - injury of, osteoarthritis and, 503-504
  - osteoarthritis of, disability in, 507
  - hereditary factors in, 505
  - natural history of, 508-509
  - prevalence of, 501-502
- Hip girdle pain, in polymyalgia rheumatica, 328
- HIV infection. *See Human immunodeficiency virus infection.*
- HLA. *See Human leukocyte antigens.*
- Hormones, in rheumatoid arthritis, 523-527
- Human immunodeficiency virus infection.
  - See also Acquired immunodeficiency syndrome.*
  - antiphospholipid antibody syndrome and, 481-482
  - inflammatory myopathies in, 661-662
  - polyarteritis nodosa and, 262, 342, 673
  - spondyloarthropathies in, 568-569
- Human leukocyte antigens, B27, in spondyloarthropathies, 559-561, 564-569
  - subtypes of, 568-569
  - in inflammatory myopathies, 659
  - in juvenile rheumatoid arthritis, 589-590
  - in rheumatoid arthritis, 521-522
  - in scleroderma, 643-644
  - in SLE, 630-632
- Hutchinson erythema elevatum diutinum, 316
- Hydroxylation status, in scleroderma, 43
- Hydroxyapatite crystals, osteoarthritis and, 506
- Hypermobility, of joint, exercise and, 894-895
- Hypersensitivity, delayed, in scleroderma, in animal models, 159-160
- Hypersensitivity vasculitis, 309-312
  - epidemiology of, 675-676
  - histopathology of, 277-280
- Hypertension, exercise and, 803-805
  - in scleroderma, treatment of, 220-222
  - pulmonary, in scleroderma, 210-211
- Hyperuricemia, asymptomatic, 544-545

coronary heart disease and, 547

epidemiology of, 539-550

Hyperviscosity syndrome, in rheumatoid vasculitis, 452

**Idiopathic inflammatory myopathies, anti-**

- Jo-1 antibodies in, 660-661
- autoimmune nature of, 660
- epidemiology of, 655-665
- etiologies of, 659-661
- exercise for, 864-865
- genetic factors in, 659
- human immunodeficiency virus infection and, 661-662
- in children, 660
- incidence of, 655-658
- prevalence of, 655-658
- prognosis for, 658-659
- serum antibodies in, 659-661
- vs. polymyalgia rheumatica, 330

Immobilization, effects of, 892-893

muscle atrophy in, 839

osteoporosis and, 729

**Immune complexes, in erythema elevatum**

- diutinum, 317-318
- in Kawasaki syndrome, 369
- in necrotizing vasculitis, 310-312
- in polyarteritis nodosa, 342
- in relapsing polychondritis, 443
- in spondyloarthropathies, 567
- in urticarial vasculitis, 315-316
- in Wegener's granulomatosis, 386

**Immunologic abnormalities, in Cogan's syn-**

- drome, 433-434
- in Kawasaki syndrome, 369-370
- in scleroderma, 45-46, 125-139, 148
  - cellular, 60-63, 126-131
  - connective tissue lesions in, 131-133
  - humoral, 125-126
  - vascular lesions and, 60-63, 131-133
- primary, antiphospholipid antibody syndrome and, 481

**Immunosuppressive therapy, in sclero-**

- derma, 210, 224-225
- in Takayasu's arteritis, 418
- in Wegener's granulomatosis, 389-390

Inactivity, arthritis and, 816-817

blood characteristics in, 818

calcium loss in, 793, 795

cardiovascular effects of, 795-798, 803-

813, 821-822

effects of, 892-893

disabling, 791-801

metabolic, 793-795

reversibility of, 799-800

exercise programs for. *See Exercise.*

fibrinogen levels in, 821-822

fibrinolysis and, 822-823

- hematocrit in, 818-820
- hematologic effects of, 815-825
- mortality and, 815-816
- muscle atrophy in, 839-840
- nitrogen balance in, 793
- platelet function in, 820-821
- without bed rest, deconditioning by, 798-799
- Inclusion body myositis, epidemiology of, 655-663
  - exercise for, 864-865
- Infection, in inflammatory myopathies, 659-660
  - in rheumatoid arthritis, 518, 522
  - Reiter's syndrome and, 554, 564-568
  - spondyloarthropathies and, 564-568
  - vs. polymyalgia rheumatica, 330-331
- Inflammation, mast cells in, 142
- Inflammatory arthritis. *See also specific disorder, e.g. Rheumatoid arthritis.*
  - exercise in, 845-870
    - active, 849
    - age considerations in, 855
    - aquatic, 867
    - assessment of joint involvement, 854-855
    - biomechanical defects and, 845-847
    - compliance with, 856
    - endurance, 852-853
    - for ankle-foot, 860
    - for cervical spine, 861, 868
    - for elbow, 861
    - for hand-wrist, 861
    - for hip, 859, 868
    - for interphalangeal joints, 868
    - for knee, 859-860, 868
    - for shoulder, 860-861
    - goals of, 848
    - in inflammatory myopathy, 864-865
    - in juvenile rheumatoid arthritis, 866-868
    - in progressive systemic sclerosis, 863-864
    - in rheumatoid arthritis, 859-862
    - in spondyloarthropathy, 865-866
    - in systemic lupus erythematosus, 862-863
  - isokinetic, 852
  - isometric, 849-850
  - isotonic, 850-852
  - joint deformity/instability and, 847-848
  - pain in, 855
  - passive, 849
  - positioning in, 866-867
  - preparation for, 855
  - prescription for, 857
  - program design for, 854-857
  - range-of-motion, 853-854, 867
  - re-evaluation of, 857
  - recreational, 854, 867
  - sequencing of, 856
  - strengthening, 867
  - stretching, 853-854, 867
  - systemic problems and, 847-848
  - types of, 848-854
- Inflammatory bowel disease, spondylitis and, 555
- Inflammatory myopathy. *See Idiopathic inflammatory myopathies.*
- Instrumental activities of daily living, disability in, 748-750
- Integrins, in fibrosis, 95-96
- Interferons, in collagen gene control, 121-122
  - scleroderma and, 62, 129
- Interleukins, in collagen gene control, 121
- scleroderma and, 20-21, 60-63, 128, 132-133
- International Classification of Diseases, disability and, 743
- International Classification of Impairments, Disabilities, and Handicaps system, 743-745
- Interphalangeal joints, exercise for, 868
- Interstitial lung disease, in scleroderma, 199-210
- Intervertebral disc, prolapsed, demographic characteristics of, 701-702
  - epidemiology of, 699-716
  - hereditary predisposition to, 709
  - in pregnancy, 708
  - incidence of, 700
  - leisure time activity and, 709
  - lumbar canal dimensions and, 706-707
  - motor vehicle driving and, 707-708
  - occupational risk factors for, 702-706
  - posture and, 708-709
  - prevention of, 709-710
  - smoking and, 707
- Isodynamic movement, 1001
- Isokinetic contraction, 1001
- Isokinetic exercise, in muscle function maintenance, 843-844
  - in shoulder impingement syndrome, 985-986
- Isokinetic testing, 994
- Isometric contraction, 1001
- Isometric exercise, 937
  - in inflammatory arthritis, 849-850
  - in muscle function maintenance, 842
  - in shoulder impingement syndrome, 984
- Isometric testing, 993
- Isotonic contraction, 1001
- Isotonic exercise, in inflammatory arthritis, 850-852
  - in muscle function maintenance, 842-843
- Isotonic testing, 993-994
- Isotretinoin, in scleroderma, 219
- Ixodes* ticks, in Lyme disease, 601-605, 609

- Jaw claudication, in giant cell arteritis, 402  
 JRA. See *Juvenile rheumatoid arthritis*.  
 Juvenile arthritis, as JRA synonym, 583-584  
 Juvenile rheumatoid arthritis, age at onset of, 587  
   chronic, 583  
   classification of, 582-583  
   diagnostic criteria for, 582-583  
   epidemiology of, 581-590  
     international collaborative studies on, 771  
   exercise for, 866-868  
   geographic distribution of, 588-589  
   hereditary factors in, 589  
   immunogenetic markers in, 589-590  
   incidence of, 584-586  
   nomenclature in, 583-584  
   prevalence of, 586-587  
   racial distribution of, 588-589  
   sex distribution of, 588  
   Takayasu's arteritis with, 414
- Kawasaki syndrome, 363-375  
   clinical features of, 363-367  
   epidemiology of, 266-267, 367-368, 676-677  
   etiology of, 266, 368-369  
   histopathology of, 286  
   immune abnormalities in, 369-370  
   pathogenesis of, 342, 344  
   roentgenographic findings in, 304  
   symptoms of, 266  
   treatment of, 370-372
- Kellgren-Lawrence classification, of osteoarthritis, 500
- Keratitis, in Cogan's syndrome, 433, 435
- Ketanserin, in scleroderma, 232
- Kidney lesions, in Henoch-Schönlein vasculitis, 281, 313-314  
   in polyarteritis, 345, 347, 350, 353  
   in relapsing polychondritis, 442  
   in rheumatoid arthritis, 518  
   in rheumatoid vasculitis, 450-451  
   in scleroderma, 8, 220-222  
   in Takayasu's arteritis, 415  
   in Wegener's granulomatosis, 378, 380, 382
- Kim-Com exercise machine, 852
- Kinanthropometry, 995-998
- Kinesiology, degenerative joint and, 989-1002  
   definitions used in, 1000-1001  
   exercise program and, 998-1000  
   fitness testing, 991-998  
   reluctant disuse, 990
- Klebsiella* infection, spondyloarthropathies and, 564-566
- Knee, arthritis of, bicycling for, 874  
   in Lyme disease, 610  
   exercise for, 859-860, 868  
   injury of, osteoarthritis and, 503-504  
   osteoarthritis of, disability in, 507  
   injury and, 828-829  
   natural history of, 508  
   obesity and, 502  
   prevalence of, 501  
   risk factors for, 506-507
- Kroc Foundation Conference on Epidemiology of Rheumatic Diseases, 770-771
- Lead exposure, gout and, 544
- Leukemia, polyarteritis nodosa in, 342
- Leukocytoclastic vasculitis (necrotizing vasculitis), 309-312
- Leukotrienes, in scleroderma, 59
- Lido exercise machine, 852
- Lifting, back pain and, 951-952, 954-957  
   in resistance training, 938
- Lipids, serum, exercise effects on, 805-806
- Livedo, in polyarteritis nodosa, 319
- Livedoid vasculitis, 320-322, 478-479
- Liver, polyarteritis of, 350-351
- Load-repetition curve, in running, 903-904
- Low back pain. See *Back pain*.
- Lung disease. See *Pulmonary disease*.
- Lupoid sclerosis, antiphospholipid antibody syndrome and, 479
- Lupus, drug-induced, 629
- Lupus erythematosus. See *Systemic lupus erythematosus*.
- Lupus-like anticoagulants, in antiphospholipid antibody syndrome, 472-474
- Lyme disease, 601-615  
   asymptomatic, 606, 608  
   causative agent of, 602-603  
   clinical manifestations of, 609-610  
   ecology of, 603-605  
   epidemiology of, 605-609  
   historical aspects of, 601-602  
   in Europe, 609-610  
   laboratory diagnosis of, 610-611  
   seronegative, 611  
   treatment of, 611
- Lymphocytes, in scleroderma, abnormalities of, 128. See also under *Endothelial cells*.  
   natural killer cell, 62-63
- Lymphoid irradiation, in scleroderma, 219
- Lymphokine activated killer cells, in scleroderma, 62-63
- Lymphokines, in scleroderma, 128-129, 132-133
- Lymphotoxin, in scleroderma, 20-21, 61
- Madecassol, in scleroderma, 219

- Major histocompatibility complex 1 genes,  
class I, 32-36  
class II, 38-41  
in scleroderma, 38-41
- Major histocompatibility complex 2 genes,  
36-38
- Major histocompatibility complex genes,  
complement components and, 36-38
- Malignant disease, in myositis, 655-663  
in polymyalgia rheumatica, 330-331, 333  
in rheumatoid arthritis, 518
- Mast cells, in fibrosis, 141-151  
in eosinophilic fasciitis, 146  
in graft-versus-host disease, 143-144  
in inflammation, 142  
in scleroderma, 145-148  
animal models of, 160-161  
in tight-skin mouse, 144  
in toxic oil syndrome, 146  
in tumors, 142  
in wound healing, 141-142  
systemic presence of, 146
- Meningitis, in Behçet's disease, 425-426
- Meniscectomy, osteoarthritis and, 829
- Metalloproteinase, chemical mediator effects  
on, 132-133
- Methotrexate, in rheumatoid vasculitis, 455-456
- Metronidazole, in scleroderma, 219
- Midaortic syndrome, in Takayasu's arteritis,  
416
- Mitochondrial antigens, antibodies to, in  
scleroderma, 178
- Mixed connective tissue disease, criteria for,  
189-190  
in children, 595  
vs. scleroderma, 189-190  
with scleroderma, 189-191
- Monocytes, abnormalities of, in sclero-  
derma, 128
- Mononeuritis multiplex, in polyarteritis no-  
dosa, 318  
in rheumatoid vasculitis, 449-451
- Morphea, in children, 594-595
- Mortality, exercise and, 807-810, 815-816
- Mucocutaneous lesions, in Behçet's disease,  
423-425
- Mucocutaneous lymph node syndrome. See  
*Kawasaki syndrome*.
- Muscle atrophy, in arthritis, 837-844, 845-846  
chronic activity effects, 839-840  
exercise programs for, 840-844  
immobilization effects, 839  
muscle fiber types and, 838-839
- Muscle pain. See *Polymyalgia rheumatica*.
- Musculoskeletal system, exercise effects on,  
827-836
- Myocardial infarction, exercise and, 807-810  
in rheumatoid arthritis, 817
- platelet function and, 820
- Myointimal cells, in vascular lesions, 54
- Myopathy, inflammatory. See *Idiopathic inflammatory myopathies*.
- Myositis, epidemiology of, 655-663  
in arthritis, 846
- Nagi's scheme for disability classification,  
743-744
- Nailfold capillary microscopy, in sclero-  
derma detection, 21-24, 78-88  
classification of, 83  
diagnostic value of, 84-85  
fluorescein videomicroscopy in, 85-86  
prognostic value of, 84-85  
semiology of, 81-83  
slow pattern in, 83  
technical aspects of, 78-81  
velocity measurements in, 86  
vs. nailfold biopsy, 86-87
- Natural killer cells, in scleroderma, 62-63
- Nautilus exercise program, 851
- Necrotizing angiitis, definition of, 270
- Necrotizing vasculitis, 309-312. See also  
specific type, e.g., *Henoch-Schönlein vasculitis*; *Polyarteritis nodosa*.
- Nemaline (rod) myopathy, in HIV infection,  
662
- Neoplasia, in scleroderma, 212
- Neurofibroma, mast cells in, 142
- Neurologic disorders, cranial, 442  
in antiphospholipid antibody syndrome,  
478-479  
in giant cell arteritis, 403-404  
in polyarteritis, 347, 349  
in relapsing polychondritis, 442  
in rheumatoid vasculitis, 449-450
- Neutral spine concept, 963-965
- Nitrogen balance, inactivity effects on, 793
- Nitrogen reductase, in spondyloarthropathies, 565-566
- Nodular vasculitis, 322
- Nodules, in granulomatous vasculitis, 323  
in polyarteritis nodosa, 318-319
- Nonspecific aortoarteritis. See *Takayasu's arteritis*.
- Nonsteroidal anti-inflammatory drugs. See  
also *Aspirin*.  
in rheumatoid vasculitis, 456
- Norepinephrine, in vascular smooth muscle  
function, 252-253, 258
- Nucleolar 7-2 ribonucleoprotein autoanti-  
bodies, in scleroderma, 177-178
- Nucleolar autoantibodies, in scleroderma,  
169-183
- Obesity, exercise and, 806-807  
in osteoarthritis, 506

- Obstetric complications, in antiphospholipid antibody syndrome, 477-478, 483, 485
- Occlusive arterial disease. See *Buerger's disease*.
- Occlusive thromboarteriopathy. See *Takayasu's arteritis*.
- Occupational factors, in low back pain, 702-706
- in osteoarthritis, 503-504
  - in rheumatic disease, in U.S.S.R., 777
  - in scleroderma, 645-646
- Oral contraceptives, rheumatoid arthritis and, 525-527
- Orthosis, for running, 902-903
- Osteoarthritis, age distribution of, 501
- bicycling in, 876-877
  - cardiovascular disease risk in, 817
  - definition of, 499-500
  - diabetes mellitus and, 506
  - epidemiology of, 499-512
    - in U.S.S.R., 776
  - exercise and, 827-836
    - generalized, 505-506
    - hereditary factors in, 505-506
  - impact of, 507-508
  - joint injury and, 502-504
  - joints affected by, 500-501
  - natural history of, 508-509
  - nodal, 505
  - nonnodal, 505
  - obesity and, 502
  - osteoporosis with, 728
  - prevalence of, 500-502, 828
  - racial differences in, 501-502
  - radiography of, vs. functional impairment, 507
  - risk factors for, 502-506
  - sex distribution of, 501
  - smoking and, 506
  - sports and, 830-832
  - symptoms of, risk factors for, 506-507
  - therapeutic exercise in, 832
  - vs. polymyalgia rheumatica, 330
  - vs. sports activity, 830
- Osteomalacia, vs. osteoporosis, 728
- Osteopetrosis, osteoarthritis and, 505
- Osteoporosis, age distribution of, 721-722
- alcohol consumption and, 725
  - bone density measurement in, 720-721
  - bone turnover in, high vs. low, 719
  - caffeine consumption and, 726
  - definition of, 718-720
  - diabetes with, 728
  - dietary factors in, 726-727
  - epidemiology of, 717-740
  - estrogens and, 722-724, 728-729
  - genetic factors in, 723
  - histologic subsets of, 719
  - immobility and, 730
  - incidence of, 717-718
  - involutional (senile, type II), 719
  - medical history and, 727-729
  - medications affecting, 729-730
  - osteoarthritis and, 505, 728
  - physical activity and, 725-726
  - strenuous training, 723-725
  - postmenopausal (type I), 719
  - primary, 719
  - racial distribution of, 722
  - reproductive history and, 723-724
  - rheumatoid arthritis with, 727-728
  - risk factors for, 721-730
  - secondary, 719
  - sex distribution of, 721-722
  - smoking and, 724-725
  - weight and, 722-723
- Otitis, in polyarteritis nodosa, 262
- in Wegener's granulomatosis, 379
- Overuse injury, in running, 897-904
- prediction of, 899-901
  - prevention of, 901-903
- Pain, back. See *Back pain*.
- disuse from, 990
  - evaluation of, 998
  - in exercise programs, 855
- PAN. See *Polyarteritis nodosa*.
- Para-aminobenzoic acid, in scleroderma, 209, 232-233
- Paranasal sinuses, Wegener's granulomatosis effects on, 379, 382, 385, 392
- Paraneoplastic syndromes, polymyalgia rheumatica and, 333
- Parasympathetic nervous system, in vascular muscle regulation, 255
- Passive exercise, in inflammatory arthritis, 849
- in shoulder impingement syndrome, 982-983
- Pediatric patients, Kawasaki syndrome in. See *Kawasaki syndrome*.
- rheumatoid arthritis in. See *Juvenile rheumatoid arthritis*.
- D-Penicillamine, in rheumatoid vasculitis, 455
- in scleroderma, 209-210, 228-230, 650
  - pulmonary effects of, 212
- Penicillin, in scleroderma, 219
- Pentazocine, scleroderma induced by, 44, 646
- Peptidoglycan, antibodies to, in spondyloarthropathies, 568
- Pericarditis, in rheumatoid vasculitis, 450
- Peripheral neuropathy, in giant cell arteritis, 403-404
- in polyarteritis, 347, 349
  - in relapsing polychondritis, 442

- Phosphate, dietary, osteoporosis and, 727  
Physical conditioning. See *Exercise*.
- Placental infarction, in antiphospholipid antibody syndrome, 477-478, 483
- Plasmapheresis, in scleroderma, 210, 233-235
- Platelet inhibitors, in scleroderma, 21, 65, 230-231
- Platelets, activation of, in scleroderma, 64-65  
aggregation of, vascular endothelium reaction to, 257  
function of, exercise and, 820-821
- Pleural disease, in rheumatoid vasculitis, 450  
in scleroderma, 212
- PM-Scl system, in scleroderma, 174-176
- Pneumoconiosis, in scleroderma, 212
- Pneumonia, aspiration, in scleroderma, 212
- Polyarteritis, microscopic, 387-388
- Polyarteritis nodosa, 341-362  
atherosclerosis pathogenesis and, 344-345  
biopsy in, 272, 353  
cause of, 342  
clinical features of, 347-351  
cutaneous, 318-319, 347, 349, 352  
diagnosis of, 352-354  
endothelial effects of, 343-344  
epidemiology of, 261-262, 341, 672-673  
giant cell arteritis with, 404  
histopathology of, 270-272  
laboratory tests in, 351-352  
pathology of, 345-347  
prognosis of, 262, 354-355  
roentgenographic findings in, 302-303  
treatment of, 262, 355-358  
cutaneous form, 319
- Polychondritis, relapsing. See *Relapsing polychondritis*.
- Polymyalgia rheumatica, 325-339  
clinical features of, 327-328  
definition of, 325  
diagnosis of, 330-332  
epidemiology of, 326, 668-671  
etiology of, 326  
giant cell arteritis and, 332-333, 402  
laboratory features of, 329-330  
malignancy and, 333  
pathogenesis of, 326  
pathology of, 327  
primary, 333  
relapses in, 335  
rheumatoid arthritis and, 333, 335-336  
treatment of, 334-336
- Polymyositis, epidemiology of, 655-663  
juvenile, 593-594  
exercise for, 864-865  
with scleroderma, 187-189
- Polymyositis-scleroderma antigen, 174-176
- Pool therapy. See *Aquatic therapy*.
- Popliteal artery, Buerger's disease of, 301  
giant cell arteritis of, 297
- Power training, in muscle function maintenance, 842
- Prednisone, in antiphospholipid antibody syndrome, 485  
in Behçet's disease, 428  
in giant cell arteritis, 406  
in polyarteritis nodosa, 355-356  
in polymyalgia rheumatica, 334-336  
in relapsing polychondritis, 444  
in rheumatoid vasculitis, 455  
in scleroderma with pulmonary involvement, 210  
in Takayasu's arteritis, 418  
in Wegener's granulomatosis, 389-390
- Pregnancy, antiphospholipid antibody syndrome in, 477-478, 483, 485  
rheumatoid arthritis during, 523-524, 527  
systemic lupus erythematosus and, 628  
Takayasu's arteritis and, 415
- Primary arteritis. See *Takayasu's arteritis*.
- Primary biliary cirrhosis, antimitochondrial autoantibodies in, 178  
with scleroderma, 191-192
- Probenicid, in gout, 548
- Procollagen peptides, fibroblast interaction with, 98-99
- Progestins, in scleroderma, 219
- Progressive systemic sclerosis. See also *Scleroderma*.  
exercise for, 863-864  
in childhood, 594-595
- Pronation, in running injury, 899-901
- Prostacyclin, in vascular muscle regulation, 255-257
- Prostaglandins, in scleroderma, 235-236
- Protein, dietary, osteoporosis and, 726-727
- Pseudoscleroderma, in children, 594-595
- Psoriatic arthritis, exercise for, 865-866  
in childhood, 591-592  
prevalence of, 562
- Psoriatic spondyloarthropathy, 554-555, 572
- Pulmonary artery, Behçet's disease of, 427-428  
Takayasu's arteritis of, 283-284, 415
- Pulmonary disease, in Churg-Strauss syndrome, 272, 275-276  
in polyarteritis, 351  
in scleroderma, 199-215  
aspiration pneumonia, 212  
drug-induced, 212  
in animal models, 158  
interstitial, 199-210  
bronchoalveolar lavage in, 204-206  
clinical features of, 199-200  
computed tomography in, 204  
histopathology of, 202-203  
lung scans in, 203-204  
pathogenesis of, 206, 208-209



- Pulmonary disease (*Continued*)  
    pulmonary function tests in, 201-202  
    radiographic features of, 201  
    treatment of, 209-210  
    neoplasia, 212  
    pleural involvement in, 212  
    pneumoconiosis, 212  
    vascular, 210-211  
    in Wegener's granulomatosis, 277, 378, 380, 382, 384-386  
Pulmonary function tests, in scleroderma, 201-202  
    Raynaud's phenomenon and, 15-16  
Pulmonary hypertension, in scleroderma, 210-211  
Pulseless disease. *See Takayasu's arteritis.*  
Purpura, Henoch-Schönlein. *See Henoch-Schönlein vasculitis.*
- Radionuclide scan, in scleroderma, esophageal motility and, 17  
    with pulmonary involvement, 203-204  
Radiotherapy, in ankylosing spondylitis, 570  
Range of motion, in resistance training, 938  
    measurement of, 992  
    of spine, 947  
Range-of-motion exercise, 999  
    in back pain, 957-960  
    in inflammatory arthritis, 853-854, 867  
    in shoulder impingement syndrome, 982-983  
Raynaud's phenomenon, cardiac manifestations of, 55-56  
    circulating cytotoxic agents in, 58-60  
    in connective tissue disease, 11-30  
    antinuclear antibodies in, 18-20  
    disease evolution in, 17-18, 24-26  
    early appearance of, 12  
    etiology of, 75-76  
    microvascular changes in, 20-21  
    nailfold capillary microscopy and, 21-24, 78-88  
    prevalence of, 12  
    subclinical findings in, 13-17  
    vs. primary Raynaud's phenomenon, 76-77  
    primary, age of onset of, connective tissue disease and, 24-25  
    antinuclear antibodies in, connective tissue disease and, 26  
    definition of, 19  
    evolution into scleroderma, 17-18, 24-26  
    histologic studies in, 24  
    severity of, connective tissue disease and, 25-26  
    vs. scleroderma, 76-77  
    scleroderma and, 131  
    as early sign, 13-17  
    as presenting symptom, 15  
    bronchoalveolar lavage in, 16  
    esophageal motility in, 17  
    histology of, 54-55  
    incidence of, 12  
    pulmonary function tests in, 15-16  
    symptoms of, 55-56  
    treatment of, platelet inhibitors in, 65  
Reactive arthritis, 554  
    course of, 571-572  
    etiology of, 564, 567-568  
    prevalence of, 561-562  
    prognosis for, 571-572  
Reagents, in antiphospholipid antibody syndrome, 472  
Recreational exercise. *See also Aquatic therapy; Bicycling.*  
    in inflammatory arthritis, 854, 867  
Red blood cells, deformability of, in scleroderma, 66  
Reiter's syndrome, 554  
    course of, 571  
    etiology of, 564-569  
    exercise for, 865-866  
    in childhood, 591  
    prevalence of, 561-562  
    prognosis for, 571-572  
Relapsing polychondritis, 441-444  
    clinical features of, 441-442  
    differential diagnosis of, 443-444  
    etiology of, 443  
    prognosis of, 442-443  
    roentgenographic findings in, 304  
    treatment of, 444  
Renal crisis, in scleroderma, 220-222  
Repetition-load curve, in running, 903-904  
Resistance training, 931-943  
    agonist/antagonist balance in, 938  
    alternative modes within, 939  
    aquatic therapy in, 939-940  
    benefits of, 931-934, 937-938  
    breathing techniques in, 939  
    equipment for, 940-941  
    in shoulder impingement syndrome, 983-984  
    levels of exercise in, 934-935  
    lifting techniques in, 938  
    range of motion in, 938  
    repetition in, 936-937  
    terminology used in, 936-937  
Rheumatoid arthritis, age distribution of, 516  
    bicycling in, 876-877  
    causes of, 519-528  
    definition of, 513-515  
    Down's syndrome and, 528  
    environmental factors in, 522  
    epidemiology of, 513-537  
        in U.S.S.R., 776

- international collaborative studies on, 771
- exercise for, 832, 859-862
- fertility and, 523-524
- fetal wastage in, 523-524
- fibrinogen levels in, 822
- fibromyalgia with, 694-695
- genetic factors in, 519, 521-522
- geographic factors in, 515
- hormonal factors in, 522-527
- incidence of, 515
- juvenile. *See Juvenile rheumatoid arthritis.*
- marital status and, 524-525
- morbidity in, 519
- mortality in, 517-519, 816-817
- oral contraceptive pill and, 525-526
- osteoporosis with, 727-728
- parity and, 524
- prevalence of, 515
- psychological stress as cause of, 528
- reproductive factors in, 532-527
- running in, 904-906
- schizophrenia and, 527-528
- secular trends in, 516-517
- senile dementia and, 528
- smoking and, 528
- Takayasu's arteritis with, 414
- vasculitis in, 284, 445-461
- clinical manifestations of, 449-451
- diagnosis of, 451-452
- digital involvement in, 447
- laboratory features of, 452-453
- pathogenesis of, 445, 448-449
- prognosis of, 456-457
- roentgenographic findings in, 304
- treatment of, 453-456
- vs. polymyalgia rheumatica, 331-332, 335-336
- with scleroderma, 193
- Rhinogenic granulomatosis, 378
- Risk factors, for rheumatic disease, 777-780.
- See also specific disease.*
- RNA polymerase I autoantibodies, in scleroderma, 173-174
- Roentgenographic findings, in vasculitic syndromes, 293-308
- Behçet's disease, 304
- Buerger's disease, 300-302, 465-467
- Cogan's syndrome, 304
- giant cell arteritis, 293-298
- Kawasaki syndrome, 304
- polyarteritis nodosa, 302-303
- relapsing polychondritis, 304
- rheumatoid, 304
- Takayasu's arteritis, 298-300, 416
- Wegener's granulomatosis, 385
- Running, 887-914
- as human act, 887-889
- degenerative joint disease from, 895-897
- flexibility in, 891-892
- hypermobile joint and, 894-895
- impact loading in, 890-891
- in arthritis patients, 904-907
- in muscle function maintenance, 841
- injury from, 897-904
- prevention of, 901-903
- pronation as predictor of, 899-901
- load-repetition curve in, 903-904
- orthoses for, 902-903
- osteoarthritis and, 504, 831-832
- repetitive load in, 903-904
- shock absorbing in, 891-892
- shoes for, 901-902
- training program for, 902
- vs. immobilization, 892-894
- work of, 889-895
- Sacroiliitis, in ankylosing spondylitis, 551-553, 556-558
- in reactive arthritis, 572
- Schizophrenia, rheumatoid arthritis and, 527-528
- Schönlein-Henoch syndrome. *See Henoch-Schönlein vasculitis.*
- Scl-70 antigen, molecular identity of, 170-171
- Scleroderma. *See also CREST syndrome; Progressive systemic sclerosis.*
- acetylation ability and, 43
- age distribution of, 3, 643
- alpha 1 antitrypsin allotypes and, 43
- animal models for, 153-167
- graft-versus-host disease and, 143-144
- induced, 153-155
- spontaneous, 155-163
- tight skin mouse line, 144, 157-163
- UCD 200 chicken line, 155-157
- antinuclear antibodies in, 18-20, 45-46, 125-126, 169-183
- autoantibodies in, 45-46, 169-183
- autoimmunity in, 129-131, 148
- beta-thromboglobulin levels in, 21
- bleomycin toxicity and, 45, 154, 167
- bronchoalveolar lavage in, 16, 204-206
- C4 null alleles and, 41-42
- C3 polymorphism and, 43
- cardiac involvement in, in animal models, 158
- cellular infiltrates in, 127
- chemical induction of, 5, 43-45, 146, 155
- chromosomal instability in, 46-47
- circulating cytotoxic agents in, 58-60
- classification of, 1-2, 641
- clinical criteria for, 1-2
- clinical manifestations of, 641, 646-648
- coagulation disorders in, 21
- collagen and, antibodies to, 126

Scleroderma (*Continued*)

- gene control of, 111-113
- production/degradation rates in, in animal models, 162-163
- type proportions in, in animal models, 161
- complement system and, 41-42, 132
- cytokines in, 128, 147-148
- cytotoxic factor in, Raynaud's phenomenon and, 20
- delayed hypersensitivity in, in animal models, 159-160
- diagnosis of, in Raynaud's phenomenon. *See Raynaud's phenomenon.*
- diffuse cutaneous, 5-7, 647-648
- drug-induced, 646
- environmental factors in, 5, 39, 43-45, 146, 645-646
- eosinophilic fasciitis with, 193-194
- epidemiology of, 1-10, 641-654
- esophageal motility in, Raynaud's phenomenon and, 17
- Factor VIII in, 66
- familial factors in, 3-5
- fibrinolysis disorders in, 66-67
- fibrosis and. *See Fibrosis.*
- genetic factors in. *See Genetic factors, in scleroderma.*
- glycosaminoglycans fraction and, 154-155
- glycosaminoglycans in, in animal models, 161-162
- graft-versus-host disease and, 131, 143-144, 153-154
- histologic studies in, 24
- hormonal factors in, 129
- human leukocyte antigens in, 643-644
- hydroxylation ability and, 43
- immunoglobulin polymorphism in, 43
- immunologic abnormalities in, 45-46, 60-63, 125-139, 148
- cellular, 60-63, 126-131
- connective tissue lesions in, 131-133
- humoral, 125-126
- in animal models, 159
- vascular lesions and, 131-133
- in childhood, 594-595
- in mixed connective tissue disease, 189-191
- incidence of, 2-3, 642-643
- late-stage, 648
- limited, 5-7, 648
- lung involvement in, 199-215
  - aspiration pneumonia, 212
  - drug-induced, 212
  - in animal models, 158
  - interstitial disease, 199-210
  - neoplasia, 212
  - pleural disease, 212
  - pneumoconiosis, 212
  - vascular disease, 210-211
- lymphocyte alterations in, 128

- lymphokines and, 128-129, 132-133
- major histocompatibility complex genes and, 38-41
- mast cell activity in, 145
- in animal models, 143-144, 160-161
- metabolic studies in, 43, 45
- monocyte abnormalities in, 128
- myointimal cells in, 54
- naifold capillary microscopy in, 21-24, 78-88
- natural history of, 5-8, 646-648
- occupational factors in, 5, 645-646
- pathogenesis of, 20-21, 146-148
  - fibroblast-matrix interactions in, 93-107
- platelet activity in, 64-65
- polymyositis with, 187-189
- prevalence of, 2-3, 642-643
- primary biliary cirrhosis with, 191-192
- prognosis for, 7-8
- pulmonary function tests in, Raynaud's phenomenon and, 15-16
- racial distribution of, 3, 643
- Raynaud's phenomenon and. *See Raynaud's phenomenon.*
- red blood cell deformability in, 66
- renal crisis in, 220-222
- rheumatoid arthritis with, 193
- sex distribution of, 3, 31-32, 643
- sine, systemic lupus erythematosus with, 186
- Sjögren's syndrome with, 191-193
- survival rate in, 7-8, 648-650
- systemic lupus erythematosus with, 186
- T-cell receptor polymorphism in, 42
- treatment of, 217-241
  - N-acetylcysteine in, 220
  - anecdotal case reports in, 217-220
  - angiotensin converting enzyme inhibitors in, 8, 220-222
  - antiplatelet agents in, 230-231
  - apheresis in, 233-235
  - colchicine in, 209, 222-223
  - cyclofenil in, 223-224
  - dextran in, 225-226
  - dimethyl sulfoxide in, 226-228
  - Factor XIII in, 231
  - immunosuppressive therapy in, 224-225
  - ketanserin in, 232
  - para-aminobenzoic acid in, 232-233
  - D-penicillamine in, 209-210, 212, 228-230
  - plasmapheresis in, 233-235
  - prostaglandin in, 235-236
- vascular disease in, 75-91, 146-147
  - characteristics of, 76-77
  - coronary, 55-56
  - endothelial cell injury hypothesis in, 56-63
  - etiology of, 75-76

- fibrosis and, 67-68  
functional observations in, 55-56  
histology of, 54-55  
immunologic factors in, 131-133  
intravascular environment in, 63-67  
lymphocyte-fibroblast interactions in, 53-73  
  naifold capillary microscopy in, 78-88  
  reperfusion injury in, 56  
vinyl chloride and, 155  
von Willebrand factor in, 21, 66  
vs. mixed connective tissue disease, 189-190
- Scleroderma overlap syndromes, 185-198**  
  eosinophilic fasciitis, 193-194  
  mixed connective tissue disease, 189-191  
  polymyositis, 187-189  
  primary biliary cirrhosis, 191-192  
  rheumatoid arthritis, 193  
  Sjögren's syndrome, 191-193  
  systemic lupus erythematosus, 186
- Sclerosis, systemic. See Progressive systemic sclerosis; Scleroderma.**
- Segmental hyalinizing vasculitis (livedoid vasculitis), 320-322**
- Senile dementia, rheumatoid arthritis and, 528**
- Serotonin antagonists (ketanserin), in scleroderma, 232**
- Serum lipids, exercise effects on, 805-806**
- Seyfield assessment protocol, in resistance training, 934-935**
- Shigella infection, spondyloarthropathies and, 564-566**
- Shoes, for running, 901-902**
- Shoulder, exercise for, 860-861**  
  pain in, in polymyalgia rheumatica, 328
- Shoulder impingement syndrome, 971-988**  
  anatomic considerations in, 971-975  
  biomechanics of, 975-976  
  causes of, 976-977  
  classification of, 977  
  evaluation of, 977-981  
  kinematics of, 975-976  
  treatment of, 981-986
- Silica dust, scleroderma induced by, 44-45**
- Silicosis, scleroderma in, 645**
- Sine scleroderma, 186**
- Sjögren's syndrome, exercise for, 864-865**  
  with scleroderma, 191-193
- Skin, vasculitis of. See Cutaneous vasculitis.**
- SLE. See Systemic lupus erythematosus.**
- Smoking, Buerger's disease and, 463-468**  
  osteoarthritis and, 506  
  osteoporosis and, 724-725  
  rheumatoid arthritis and, 528
- Sneddon's syndrome, antiphospholipid antibodies and, 478-479**
- Sociomedical model, of disability, 746-747**
- Speed training, in muscle function maintenance, 842**
- Spine, "neutral," 963-965**
- Splenomegaly, in rheumatoid vasculitis, 450**
- Spondyloarthropathies, classification of, 563-564**  
  course of, 570-572  
  epidemiology of, 551-579  
    in children, 590-592  
    international collaborative studies on, 771  
  etiology of, 564-569  
  exercise for, 865-866  
  human leukocyte antigens in, 559-562, 564-569  
  late-onset, 553-554  
  of childhood, 590-592  
  prevalence of, 555-564  
  prognosis for, 570-572  
  psoriatic, 554-555  
  spectrum of, 551-555  
  undifferentiated, 555
- Sports, impact of, 895-897**  
  osteoarthritis and, 503-504, 830-832  
  osteoporosis and, 723-726, 730  
  shoulder impingement syndrome in. See *Shoulder impingement syndrome.*
- Stanford Health Assessment Questionnaire, 750**
- Steroid medications, osteoporosis and, 728**
- Still's disease, 583**
- Stomatitis, in Behçet's disease, 423**
- Strength, assessment of, 992-994**
- Strengthening exercise, 999-1000**  
  in back pain, 960-963  
  in juvenile rheumatoid arthritis, 867  
  in shoulder impingement syndrome, 984-985
- Stress erythrocytosis, in inactivity, 819-820**
- Stretching exercise, 1000**  
  in inflammatory arthritis, 853-854, 867
- Subclavian artery, giant cell arteritis of, 294-296**
- Sulfinpyrazone, in gout, 548**
- Swimming. See Aquatic therapy.**
- Sympathetic nervous system, in vascular muscle regulation, 254-255**
- Synovitis, in polymyalgia rheumatica, 327-328, 331**
- Syphilis, false-positive tests for, in antiphospholipid antibody syndrome, 472**
- Systemic lupus erythematosus, age distribution of, 621-622**  
  in children, 593  
  classification of, 617-618  
  endocrine factors in, 626-628  
  environmental factors in, 593, 629-630  
  epidemiology of, 617-639  
  in children, 592-593

- Systemic lupus erythematosus (*Continued*)  
 international collaborative studies on, 771  
 etiology of, 625-632  
 exercise for, 862-863  
 genetic factors in, 593, 630-632  
 geographic distribution of, 592  
 in childhood, 592-593  
 incidence of, 592, 620-621  
 metabolic factors in, 626-628  
 morbidity data for, 619-623  
 mortality data for, 623-625  
 pregnancy outcome in, 628  
 prevalence of, 592, 619-620  
 prognosis for, 632-633  
 racial distribution of, 592, 621-622  
 sex distribution of, 593, 621-622  
 survivorship in, 632-633  
 vasculitis in, 284, 316  
 with scleroderma, 186
- Systemic sclerosis. *See Progressive systemic sclerosis; Scleroderma.*
- Takayasu's arteritis, 411-422  
 classification of, 416-417  
 clinical features of, 413-415  
 criteria for, 417  
 diagnosis of, 300, 416-417  
 epidemiology of, 264-265, 411-412, 671-672  
 etiology of, 411-413  
 genetic factors in, 412-413  
 histopathology of, 282-284, 412  
 roentgenographic findings in, 298-300, 416  
 treatment of, 417-419
- Temporal arteritis, giant cell. *See Giant cell arteritis.*  
 non-giant cell, 351
- Temporal artery, biopsy of, 336
- Testis, polyarteritis of, 351
- Th<sub>0</sub> antibodies, in scleroderma, 177-178
- Thiazide diuretics, osteoporosis and, 728
- Thromboangiitis obliterans. *See Buerger's disease.*
- Thrombocytopenia, in antiphospholipid antibody syndrome, 476-477
- Thrombophlebitis, in antiphospholipid antibody syndrome, 479  
 in Buerger's disease, 465-466
- Thrombosis, in antiphospholipid antibody syndrome, 475-476, 482-484  
 venous, in Behçet's disease, 426-427
- Thromboxane, in scleroderma, 64-65
- Thyroid hormone replacement, osteoporosis and, 728-729
- Tibial artery, giant cell arteritis of, 297
- Ticks, in Lyme disease, 601-605, 609
- Tissue plasminogen activator, exercise and, 823
- To<sub>0</sub> antibodies, in scleroderma, 177-178
- Tobacco, Buerger's disease and, 463-468
- Toxic oil syndrome, 595, 646  
 mast cell activity in, 146
- Transforming growth factors, in collagen gene control, 120-122  
 in scleroderma, 62, 132-133
- Trichloroethylene, scleroderma induced by, 43-44
- Triglycerides, exercise effects on, 805-806
- Trimethoprim-sulfamethazole, in Wegener's granulomatosis, 390-392
- L-Tryptophan, in eosinophilia myalgia syndrome, 646
- Tumor(s), mast cells in, 142
- Tumor necrosis factor, scleroderma and, 61, 132-133
- U3-RNP-associated fibrillar autoantibodies, in scleroderma, 176-177
- Ulceration, in antiphospholipid antibody syndrome, 479  
 in Behçet's disease, 423-425  
 in granulomatous vasculitis, 323  
 in livedoid vasculitis, 320-322
- Ulcerative colitis, with arthritis, in childhood, 592
- Union of Soviet Socialist Republics, epidemiologic studies in, 773-781
- United States Senate Committee on Government Operations, rheumatic disease report of, 766-767
- Uric acid, excess blood levels of (hyperuricemia), 539-550
- Uricosic agents, in gout, 547-548
- Urticarial vasculitis, 315-316
- Uveitis, in Behçet's disease, 425
- Valvular disease, in antiphospholipid antibody syndrome, 480
- Vasculitic syndromes. *See also specific disorders.*  
 antiphospholipid antibody syndrome and, 471-490  
 Behçet's disease and, 304, 423-431  
 Buerger's disease (thromboangiitis obliterans), 287-290, 300-302, 463-470  
 central nervous system angitis, 287  
 Churg-Strauss syndrome, 262-263, 272-277, 377-397, 404  
 classification of, 269-270  
 Cogan's syndrome and, 304, 433-439  
 cutaneous. *See Cutaneous vasculitis.*  
 diagnostic histopathology of, 269-292

- epidemiology of, 261-268, 667-690  
 Churg-Strauss syndrome, 674  
 giant cell arteritis, 668-671  
 Henoch-Schönlein vasculitis, 675-676  
 Kawasaki syndrome, 676-677  
 polyarteritis nodosa, 672-673  
 polymyalgia rheumatica, 668-671  
 Takayasu's arteritis, 671-672  
 Wegener's granulomatosis, 674-675  
 erythema elevatum diutinum, 316-318  
 giant cell arteritis. *See* *Giant cell arteritis*.  
 granulomatous vasculitis. *See* *Granuloma-*  
*tous angiitis/vasculitis*.  
 Henoch-Schönlein vasculitis, 262-264,  
 281, 313-315  
 histopathology of, 269-292  
 hypersensitivity vasculitis, 277-280, 309-  
 312  
 in connective tissue disease, 284-286  
 in scleroderma. *See* under *Raynaud's*  
*phenomenon*; *Scleroderma*.  
 Kawasaki syndrome. *See* *Kawasaki syn-*  
*drome*.  
 livedoid vasculitis, 320-322  
 necrotizing vasculitis, 309-312  
 nodular, 322  
 pathophysiology of, 259  
 physiology of, 251-260  
 polyarteritis nodosa. *See* *Polyarteritis no-*  
*dosa*.  
 polymyalgia rheumatica, 325-339  
 relapsing polychondritis and, 441-444  
 rheumatoid arthritis and, 284, 304, 445-  
 461  
 roentgenographic findings in, 293-308.  
*See also* specific disease.  
 Takayasu's arteritis. *See* *Takayasu's arte-*  
*ritis*.  
 urticarial vasculitis, 315-316  
 Wegener's granulomatosis, 263, 277, 377-  
 397, 443  
 Vasculitis, definition of, 269  
 Vasoactivity, endothelial injury and, 343  
 regulation of, 251-259  
 Vegetarianism, osteoporosis and, 727  
 Vena cava, Behçet's disease of, 426-427  
 Venous occlusive disease, in Behçet's dis-  
 ease, 426-427  
 Vibration, back pain and, 706  
 Vinyl chloride, scleroderma induced by, 43-  
 44, 155, 645  
 Viral infections, inflammatory myopathies  
 and, 659-660  
 polyarteritis and, 342-343  
 Visceral arteries, Buerger's disease of, 301  
 polyarteritis nodosa of, 302-303, 347, 350  
 Takayasu's arteritis of, 299  
 Vitamin D, osteoporosis and, 727  
 von Willebrand factor, in polymyalgia rheu-  
 matica, 329-330  
 in scleroderma, 21, 66  
 Walking, as exercise, 887-914. *See also*  
*Running*.  
 effects of, 895-897  
 work of, 889-895  
 Warfarin, in antiphospholipid antibody syn-  
 drome, 484-485  
 in scleroderma, 219  
 Water exercises. *See* *Aquatic therapy*.  
 Wegener's granulomatosis, 377-397  
 anticytoplasmic autoantibodies in, 386-  
 389  
 biopsy in, 385  
 clinical features of, 378-384  
 course of, 382, 384  
 diagnosis of, 277, 385-389  
 ELK-classification of, 381-382  
 epidemiology of, 263, 674-675  
 etiology of, 263  
 histopathology of, 277  
 pathology of, 384  
 prognosis of, 263  
 roentgenographic findings in, 385  
 treatment of, 263, 389-392  
 vs. relapsing polychondritis, 443  
 Weight training, in muscle function mainte-  
 nance, 843  
 Whipple's disease, 555  
 Wiskott-Aldrich syndrome, antiphospholipid  
 antibody syndrome and, 481  
 Work disability, 748-750  
 Wound healing, mast cells in, 141-142  
 Yersinia infection, spondyloarthropathies  
 and, 564, 567, 572  
 Zeek classification, of vasculitides, 270  
 Zidovudine, myopathy from, 662